Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

"The best medication for Parkinson's will come from Israel. It will be a hybrid medication, and the world's best hybrid ...

If you notice more than one of these symptoms, it's worth discussing them with your doctor. Trouble Moving or Walking ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...

Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and ...

"Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...